Rumor mill churning as possible Pfizer/AstraZeneca Round 2 approaches

Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this week. And while analysts have been abuzz with the possibilities of a backup bid for Actavis ($ACT) or even GlaxoSmithKline ($GSK), AZ ($AZN) seems to remain the coveted megamerger/tax inversion target that could have the impact Pfizer ($PFE) needs. More